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A B S T R A C T
Background: Decisions about the use of new technologies in health
care are often based on complex economic models. Decision makers
frequently make informal judgments about evidence, uncertainty, and
the assumptions that underpin these models. Objectives: Transparent
interactive decision interrogator (TIDI) facilitates more formal critique of
decision models by decision makers such as members of appraisal com-
mittees of the National Institute for Health and Clinical Excellence in the
UK. By allowing them to run advanced statistical models under different
scenarios in real time, TIDI canmake the decision process more efficient
and transparent, while avoiding limitations on pre-prepared analysis.
Methods: TIDI, programmed in Visual Basic for applications within Ex-
cel, provides an interface for controlling all components of a decision
model developed in the appropriate software (e.g., meta-analysis inWin-
BUGS and the decision model in R) by linking software packages using
RExcel andR2WinBUGS.TIDI’s graphical controls allow theuser tomodify
assumptionsand to run thedecisionmodel, and results are returned toan
Excel spreadsheet. A tool displaying tornado plots helps to evaluate the
influence of individual parameters on themodel outcomes, and an inter-
activemeta-analysismodule allows the user to select any combination of
available studies, explore the impact of bias adjustment, and view results
using forest plots. We demonstrate TIDI using an example of a decision
model in antenatal care. Conclusion: Use of TIDI during the NICE ap-
praisal of tumor necrosis factor-alpha inhibitors (in psoriatic arthritis)
successfully demonstrated its ability to facilitate critiques of the deci-
sion models by decision makers.
Keywords: bias adjustment, decisionmodel, interactive, meta-analysis,
RExcel, software, TIDI
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Introduction
Decision-making systems in health care are increasingly designed
in such away to ensure equity of access and to optimize the use of
limited health care resources, and this approach has been adopted
now in many countries. To aid the decision-making process,
health technology assessments (HTAs) are performed that evalu-
ate both the effectiveness and cost-effectiveness of new technol-
ogies compared to existing technologies, resulting in guidance to
national health care services. A significant component of HTAs is
the economic evaluation that often relies on the development of
elaborate decision analytic models [1,2]. Such models require a
large number of inputs (related to cost, clinical effectiveness, nat-
ural disease history, and/or quality of life), some of which may be
obtained from primary data collection, but more often rely on the
re-analysis of published or other secondary data [3].
Historically, a two-part approach to HTA has been adopted,
where individual parameter estimates are first obtained either di-
rectly or by conducting preliminary analyses (e.g., ameta-analysis
where multiple sources of evidence exist) and then extracted and
input into a decision model, often assuming independence and
parametric distributions [4]. More recently an integrated one-step
approach has been advocated [4,5] that unifies the two stages de-
scribed above where all preliminary analyses and the decision
model are conducted within a single analytical framework. The
main advantages of this integrated approach over a two-stage ap-
proach include relaxing the assumptions of independence and
parametric distributions, and the facilitation of transparency, sen-
sitivity analysis, and updating. To date this has been achieved by
programming all analysis components and evaluating them
within a single statistical program. Markov Chain Monte Carlo
simulation, as implemented in theWinBUGS package [6], provides
an ideal environment for this. However, despite the advantages of
such an approach, limitations include 1) lack of a user-friendly
interface, and 2) very limited numerical and graphical output fa-
cilities. This makes it very difficult for models constructed in this
way to be interrogated and fully appraised by non-technical ex-
perts including decision makers.
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Decision making on new health care technologies in England
and Wales is conducted by the National Institute for Health and
Clinical Excellence (NICE). Health technology appraisal documents
are produced both by independent academic teams andmanufac-
turers, for consideration by NICE appraisal committees. Having
carefully appraised these documents, the committees have to
make decisions based on their own informal judgments about the
evidence, uncertainty, and assumptions made [7,8]. Often the ap-
praisal documents contain decision analyticmodels that are prob-
abilistic in nature and thus reflect parameter uncertainty to some
degree. However, usually uncertainties exist beyond those quan-
tified in this way (e.g., parameters for which no data exist, struc-
tural uncertainties in the decision models). Hence, sensitivity
analysis is an important part of the decision-making process and
is used to investigate the robustness of the model results across
different scenarios. This usually entails analysts anticipating, run-
ning, and reporting all possible scenarios that might be of interest
to decision makers prior to their discussions. However, where all
scenarios of interest have not been anticipated, this can lead to an
inefficient process of repeated evaluations as analysts respond to
sequential requests from decision makers (or decisions are made
without the opportunity to formally conduct the relevant analy-
ses). Therefore, it would be advantageous to allow decision mak-
ers, such as the appraisal committees of NICE, to run analyses
under different scenarios, ideally in real-time during actual com-
mittee discussions.
In this report we introduce the framework concept of a
transparent interactive decision interrogator (TIDI) together
with an illustrative example implementation. This enhances
the integrated one-stage approach discussed above, by incorpo-
rating a user interface to control many aspects of the modeling
(i.e., preliminary analyses and evaluation of the decision
model). It has been designed to help to overcome problems of
interpretation, clarity and transparency in the decision process
by facilitating critiques of the model structure, assumptions
and uncertainty by a broad spectrum of people ranging from the
analysts themselves when developing the model through to
non-technical decisionmakers and other stakeholders. TIDI has
been developed to be used in real-time by committees such as
those at NICE during their deliberations. Hence, TIDI can make
the process of evaluating uncertainty more transparent, faster,
and more efficient; while at the same time avoiding arbitrary
limitations of pre-prepared analyses of a restricted number of
scenarios that might compromise its validity. A further techni-
cal advancement made possible by this approach is a relaxation
of the need for all components of the modeling to be conducted
in a single piece of code using MCMCmethods. As we describe in
more detail below, the TIDI interface can control multiple sep-
arate modeling components conducted in packages such as (but
not restricted to) R andWinBUGS and coordinate them in such a
way to maintain a one-step approach to analysis. This allows
the utilization of the strengths of each package while overcom-
ing their individual limitations.
The remainder of this article will 1) describe how TIDI works at a
conceptual level; 2) introduce a range of features that can be imple-
mented through an illustrative example decision model; and 3) pro-
vide a brief account of our experience piloting the interface at a real
NICE technology appraisal committee meeting. The discussion will
provide some closing remarks.
While we don’t intend this article to present a software tu-
torial on “how to program a TIDI interface,” we do provide all
code developed for the illustrative example. The instructions on
how to use the interface and how to install necessary software
are included in Appendix A, which can be found at doi:10.1016/
j.jval.2010.12.002.
Methods
Developing TIDI
There are a number of software packages available to implement
health economic models. Although Excel (Microsoft Corporation,
Redmond,WA) ismostly accessible and known to awider commu-
nity of nonexperts, decision models designed using Excel spread-
sheets tend to be incomprehensible by the nature of the way they
are constructed on an underlying spreadsheet. There have also
been reports of Excel built-in statistical functions and procedures
being faulty [9] or based on nonstandard rules of operator prece-
dence [10]. Hence, we wished to keep the familiarity of Excel and
the flexibility it allows for developing graphically appealing and
intuitive “point and click” front-end control panels, while imple-
menting the decision model and any subsidiary analyses (such as
meta-analyses,modeling of individual level data sets, etc) in pack-
ages more suited for these tasks. Thus, TIDI’s decision models
have been developed in the specialized statistical packages R [11]
and/or WinBUGS [5] as we believe these are clearer, more flexible,
transparent, and computationally efficient, as well as allowing
analysis methods not possible in Excel such as network meta-
analysis [12]. However, the use of these specialized packages is
entirely “behind the scenes”: the Excel-based user interface allows
decision makers to have access to features of all components of a
decision model developed in R and WinBUGS without a need of
knowledge of these software packages. This Excel front-end not
only makes it possible to change the assumed values or distribu-
tions of the model parameters and re-run models under different
scenarios in real time, but can also provide a control over the
model assumptions. TIDI can also provide interactive access to
supplementary analyses, for example influence analysis that can
help to establishwhich of the parameters have themost impact on
the cost-effectiveness estimates, and the meta-analyses carried
out to estimate the efficacy parameters. A specific meta-analysis
module of TIDI can enable interactive inclusion/exclusion of stud-
ies as well as bias adjustment [13] in real time for any such anal-
yses contributing to decision model parameter estimation.
An Excel-based interface, programmed in Visual Basic for ap-
plications (VBA; Microsoft Corporation) [14,15], is at the center of
TIDI. This allows a range of assumptions to be changed by using
graphical controls set out on the Excel spreadsheet. RExcel [16,17],
which is an add-in to Excel, provides communication between
Excel and R. All data used by themodel components can be stored
in the Excel spreadsheets and transferred to the R workspace and
various actions, for example execution of the decision model or its
components, can also be activated using controls located on the Ex-
cel spreadsheet. Results of the decision model are then transferred
from R back to Excel via RExcel. R also has powerful and flexible
graphical capabilities, and output can be represented graphically in
Excel using customplots created “on thefly” inR (a tutorial onhowto
constructa simpleExcel interface linked toRcodecanbe found in the
RExcelmanExcel interface linked toRcodeualwith “demo”examples
provided by the authors of RExcel with the download of the soft-
ware).
Having this possibility of running programs developed in R from
Excel allows the user to take this further and to execute (from Excel)
additional model components, including complex evidence synthe-
ses developed in WinBUGS [18]. This is achievable by using the
R2Winbugs package available in R [19]. R2WinBUGS provides addi-
tional R commands thatmake it possible to specify (in the R code) all
data and parameters necessary for theWinBUGS code to run. In this
way, usingRExcel, data required to runWinBUGS code canbepassed
from the Excel spreadsheet to the R workspace from which R code
(run from Excel via RExcel) sends it to WinBUGS together with the
instructions on how to process these data. This framework for the
transfer of data and commands between different pieces of software
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is shown schematically in Figure 1. An important principle in this
approach is that it is necessary to keep estimation of correlated pa-
rameterswithin the sameanalysis component. If this principle is not
adhered to then the correlations between parameters will be lost
within the evaluation of the decision model.
It is important to note that it would be possible to connect
further packages into a TIDI interface. For example, routines are
available that allow SAS (SAS Institute, Cary, NC) and Excel to
communicate [20], and Stata 10 (StataCorp LP, College Station, TX)
allows direct exportation to EXCEL format (and communication
between STATA and WinBUGS has been developed [21]). Gener-
ally, any package that can be controlled using a scripting language
(or already has an Excel interface, such as TreeAGE [TreeAge Soft-
ware, Inc., Williamstown, MA]) can be used. Since HTAs are often
conducted by multidisciplinary teams, and specialists may have
different software preferences and knowledge, we believe the cre-
ation of a TIDI type control panel in Excel may have the added
benefit of “harmonizing” analysis components.
Illustrative example: Routine antenatal anti-D prophylaxis
for Rhesus D-negative pregnant women
Wepresent an illustrativeTIDI application thatwas implemented for
aneconomicdecisionmodel developed for theNICEappraisal of rou-
tine antenatal anti-D prophylaxis (AADP) for Rhesus D (RhD)-nega-
tive pregnant women [22]. RhD-negative women carrying an RhD-
positive fetus can develop anti-D antibodies (RhD sensitization
process) that can affect subsequent pregnancies, potentially leading
to hemolytic disease of the newborn. Anti-D prophylaxis is used to
reduce the incidence of sensitization. The decisionmodel evaluated
whether four anti-D treatments are cost-effective when adminis-
tered to RhD-negative pregnant women who are in their first preg-
nancy or to all RhD-negative pregnant women.
This example has also been used by Turner et al. [13] to develop
methods for modeling bias in evidence synthesis, where authors
used the effectiveness data from the first NICE appraisal of anti-D
prophylaxis [23]. These methods have been implemented in TIDI as
part of its interactive meta-analysis module to illustrate how TIDI
brings such cutting-edge approaches to analysis within the grasp of
non-technical experts.
Interface capabilities
Constructing a model scenario
The controls for the model parameters and actions are set out on
the front Excel worksheet of the TIDI control interface, called
“SetupAndRun.” These controls allow assumptions about the
values and associated uncertainty of the parameters informing
the decision model to be changed (see elsewhere for a full de-
scription of the model and its assumptions [22]). Figure 2 shows
the layout of these controls. The controls can be designed to allow
theuser to switchbetweenalternative options formodeling the cost-
effectiveness. For example, in this interface the “radio” buttons en-
able switchingbetweenadeterministic or stochastic (i.e., incorporat-
ing uncertainty) model. This approach potentially allows the user to
have access to the model parameter values and model structure,
assumptions, and leads to building newmodel scenarios.
Decision model execution and results
Once anewmodel scenario has been built, themodel can be re-run
by pressing the “Run Model” button. All model parameter values
are then loaded into an R workspace where the R2WinBUGS com-
mands are used to send data to and execute code in WinBUGS (in
this example the decision model is programmed in WinBUGS);
then the outcome information is sent back to the Rworkspace. The
range of outcomes for this model consists of costs, incremental
costs (per sensitized woman, affected fetus, fetus lost, life year
gained, and quality-adjusted life year gained), incremental net
monetary benefit (INMB) and other clinical outcomes. The results
of themodel are automatically transferred into the “output” work-
sheet via RExcel. As shown in the example in Figure 3, the “output”
spreadsheet lists costs, outcomes of the economic model, and
other outcomes of clinical interest for strategies 1–3 (strategy 1:
control group, conventional management; strategy 2: AADP to pri-
migravida only; strategy3: AADP to all RhD-negative pregnant
women). For the stochastic model, a graph showing the cost-
effective acceptability curves [24] is constructed in R but dis-
played in Excel. This shows the probabilities of each treatment
and strategy combination being cost-effective compared to the
alternatives, under a range of willingness to pay thresholds.
Additionally, the interface provides various ways for storing in-
formation, for example, on origin of the parameters’ estimates used
in themodel. Also, full sets of data corresponding todifferent scenar-
ios can be stored and accessible in an interactivemanner asdescribed
in Appendix B, which can be found at doi:10.1016/j.jval.2010.12.002.
Meta-analysis module
In this model, effectiveness estimates (odds ratio [OR] here are all
interventions assumed to have the same effectiveness [22]) that in-
form the decisionmodel are obtained from ameta-analysis. The de-
velopedmeta-analysismodule of TIDI allows the user to have access
tomanydetails of the analysis and tomake someadjustments to the
evidencesynthesis.Themeta-analysis interface isdesigned insucha
way to enable selection of any subset of available studies for which
pooled outcomes can be recalculated. For example, if a committee
member raises doubts about the quality or relevance of a particular
study, it is easy to exclude this study and re-run the meta-analysis
from the Excel front end. The resulting estimates are then displayed
in tabular formaswell as using interactive forest plots. The outcome
of the new meta-analysis (OR) can then be uploaded into the front
worksheet containing themodel parameters and the decisionmodel
can be re-run with the amended effectiveness estimates.
This sensitivity analysis can be vital in situations when some of
the available studies are, for example, of questionable quality or do
not represent the considered population of patients. However, we go
beyond this simple sensitivity analysis and allow for adjustment of
results from individual studies in the meta-analysis for the various
potential internal and external biases as those considered by Turner
et al. [13], based on information from expert elicitations and using a
Bayesian method. The interface enables the user to choose which
types of bias to adjust for. The user can decide whether or not to
adjust for internal biases reflecting the lack of rigor of studies in-
cluded in the meta-analysis, or for external biases that relate to the
relevance of those studies included, such as their short comings in
answering the target question. The decision maker can also decide
whether (within those internal and external biases) to adjust only for
biases that act additively or for those believed to be proportional to
theeffectof the intervention. InadditionTIDI enables selectionof the
specific bias assessors to be included in the bias-adjustedmeta-anal-
Fig. 1 – Transfer of data and commands between the
software packages.
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ysis, allowing sensitivity to which expert opinions are incorporated
to be assessed.
Figure 4 displays the front end of the meta-analysis module and
the tick boxes for study, bias type, and assessor selection. The results
are provided in tabular form and also with interactive forest plots.
After selecting the studies, types of biases and the bias assessors to
be included, themeta-analysis can be re-run (by pressing the button
“Run meta-analysis”) and updated estimates are then displayed in
theupdated forest plots inwhich the results of theunadjustedmeta-
analysis are also displayed (grayed-out) for comparison. In the lower
“forest plot” the impact of the included bias on the meta-analysis
estimates is displayed in more detail for information. Pressing the
Fig. 2 – The front page of TIDI with setup of the model parameters.
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button “Load adjusted OR into the decision model” sends the new
estimate of the OR to the front spreadsheet of TIDI (“SetupAndRun”)
and replaces the original value with the new estimate, which can
then be used in a new scenario of the decision model.
Influence analysis module
Health economic decision models can be very complex, being in-
formed by a large number of inputs related to the cost and effec-
tiveness of treatments. It is infeasible to carry out a sensitivity
analysis that explores all possible scenarios considering different
values of all parameters. Influence analysis can help to identify
those parameters that have the highest impact on the cost-effec-
tiveness estimates such as INMB or incremental cost-effective-
ness ratio (ICER), and can be represented by means of tornado
plots [25]. Figure 5 shows an example of the (deterministic) tor-
nado plot for INMB calculated for Partobulin, comparing strategies
2 and 1. The parameters most influential for this INMB (indicated
by thewidest bars at the top of the plot) are the annual discount for
effectiveness and the sensitization ratewithout routine AADP (i.e.,
control group event rate). The bottom bar shows the INMB with
95% CI obtained from the stochasticmodel (for the base case set of
parameters) for comparison. Further details on tornado plots and
their stochastic counterparts can be found in Appendix B at doi:
10.1016/j.jval.2010.12.002.
Use of TIDI in practice
TIDI has also been developed for an economic model (and associ-
ated evidence syntheses) commissioned by NICE assessing the
cost-effectiveness of tumor necrosis factor alpha (TNF-alpha) in-
hibitors (etanercept, infliximab, and adalimumab) when used in
treatment of psoriatic arthritis [26]. This interface was used by the
NICE technology appraisal committee during their meetings to
support their decision-making process. We have not been able to
present this TIDI application in this report for reasons of confiden-
tiality. It was created for a more complex model (compared to the
decision model considered here) and it gave opportunity to ex-
plore, for example, alternative ways of modeling utility, the im-
pact of alternative stopping rules in the Markov model, or sub-
group analyses. The meta-analysis module of this interface
contained multiple evidence syntheses including network meta-
analyses. Also, in addition to output of the decision model in-
Fig. 3 – The output page of TIDI displaying all results of the decision model and acceptability curves plot.
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cluded in the Anti-D example above, a plot formarginal cost effec-
tiveness of the various alternative interventions was constructed.
During the committee meetings, the interface was used—in real
time—to answer some queries from the committee members
about the assumptions regarding clinical effectiveness of the in-
terventions and their impact on the cost-effectiveness estimates.
For this technology appraisal, the assessment group carried
out cost-effectiveness analysis across 31 sensitivity analysis sce-
narios [27]. It coveredmany aspects of themodeling in terms of the
parameter values and structure of the model. Despite this very
comprehensive analysis, the committee members still had ques-
tions about some of themodel assumptions and their effect on the
estimates from the economic decision model. To answer these
questions, additional scenarios beyond those presented in the
pre-prepared analysis were required. The scenarios, considered
during the committee meeting, included an analysis which as-
sumed that adalimumab and etanercept were equally effective
(while the responses for infliximab remained the same as in
the original analysis). The decision model was re-run with alter-
native parameter values using the TIDI interface during the com-
mittee meeting to provide an immediate answer to the queries
which had arisen. An additional scenario was considered where
the cost of one of the interventions depended on the way of ad-
ministering it. The committee also inquired about the effect of
removing one of the studies from the meta-analysis on the out-
comes of the decision model. There was a concern that the popu-
lation in this studywas not representative of the target population
and thus may provide a biased estimate of effect. The authors of
this manuscript, who attended the committee meeting (S.B.,
A.J.S.), were able to re-run the meta-analysis after removing the
Fig. 4 – Meta-analysis module of TIDI with bias adjustment options.
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study (using the interactive interface) and then re-run the decision
model using the updated effectiveness estimates.
The delay caused by running the model was not substantial; it
took between 1 and 2 minutes to run the model and an additional
2 minutes to run the meta-analysis. The committee was able to
continue their discussions while the model was executed. How-
ever, due to the complexity of this particular model, only the de-
terministic version was used in real-time (the stochastic model
could take several hours to run). The results were later confirmed
by running the full probabilistic model; which we were confident
would be the case since we had used the TIDI interface to monitor
the error (which was small) across all pre-prepared scenarios
prior to the committee meeting. This subsequent analysis was
performed only for the scenario considering equal effectiveness
of etanercept and adalimumab, and the remaining two addi-
tional scenarios mentioned above were not relevant to the de-
cision.
Following the meetings, the authors surveyed the committee
members about the usefulness of TIDI. Most of the responders
were very positive about TIDI fulfilling its objectives of 1) giving
support to the decision makers by allowing them to explore evi-
dence syntheses and decision models under different scenarios
and assumptions in real time, and 2) making the decision-making
process faster andmore efficient; while at the same time avoiding
arbitrary limitations of the (pre-prepared) analysis that might
compromise its validity. The committee found seeing the results
helpful and although, in this particular appraisal, the answers to
the committee’s queries did not provide unexpected or decision-
changing answers, the committee members appreciated that a lot
of the time it is not clear what the effect of a change in assump-
tions would have on the outcomes. The responders to our survey
also believed that it would be very desirable to make an interface
like TIDI available routinely at NICE technology appraisal commit-
tee meetings. Although, not all committee members found it easy
to understand the interface and the output it produced, all of the
responders thought it would be desirable for the interface to inte-
grate with the appraisal report in terms of presentation as well as
content. We found that the members of the committee who were
introduced to TIDI before the appraisal meeting were able to un-
derstand it better and appreciate it more than those who did not
get such an introduction (due to time constraints only the briefest
introduction was possible in the committee meeting). Overall we
had a strong impression that TIDI can be a useful tool for the NICE
committees, especially if the interface was introduced to the
members in advance to make it easier for them to follow it during
a dynamic discussion and if the interface is clearly readable (our
font size was initially too small for the projection conditions).
Discussion
TIDI has been created as a concept with the aim of helping the
decision makers who are non-statistical experts, such as many
members of the NICE appraisal committees, to make their deci-
sion process more transparent and efficient. It provides a tool to
critique and explore the decision models and evidence syntheses
(by which these models are informed) by a wider community of
decisionmakers, not only those familiar with specialized software
packages such as R andWinBUGS. It potentially allows the user to
have in-depth access to and control over values/distributions on
all model parameters andmodeling assumptions, and at the same
time uses flexible, clear, and hence transparent model compo-
nents developed in R and WinBUGS. By making it possible to run
models in real time, it makes the decision process more efficient.
Fig. 5 – Example of tornado plot for Partobulin and comparison of strategy 2 versus 1.
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Being able to re-run a model under new scenarios in real time not
only allows sensitivity analysis that potentially can change the
final decision but also provides reassurance that, for example, un-
certainty about a particular parameter does not have much effect
on the cost-effectiveness estimates. Any required additional
model scenarios or the interpretation of evidence can be consid-
ered during the committee meetings without the need for the
committee to delay a decision and reconvene. It also allows an
integrated analysis even when components of the modeling have
been carried out in different packages.
As part of the process for developing a TIDI interface for use in
“real-time,” we investigated the speed of varying software configu-
rations. For illustration, theAnti-D stochasticmodel implemented in
WinBUGS, when executed from TIDI (i.e., the version we havemade
available with this article), takes about 1.5 minutes to run 5000 iter-
ations (without loss of speed compared to running the model di-
rectly from R using R2WinBUGS). It takes about 20 minutes to ex-
ecute 5000 iterations of the same model developed entirely in
Excel. The same model, implemented in R only, runs 5000 itera-
tions in about 1.5 minutes. Hence we believe speed should also be
a factor when deciding which combination of packages to use and
significant speed improvements can be gained from using Win-
BUGS or R over using Excel for the whole application.
TIDI can be developed further to accommodate more complex
decisionmodels. For example the interface can havemore options
built into the “SetupAndRun” front page reflecting alternative as-
sumptions about the model structure. Option buttons may allow
the user to switch between different ways of modeling utility and
cost over time, alternative parametric ways of modeling survival
data or various alternative options defining stopping rules in
Markov decision models, depending on the needs and complexity
of the economic model. The part of the interface displaying the
model results can also be designed in a number ofways depending
on the needs of the decision makers. For example, when decision
models are designed to comparemore than two interventions, the
ICERs resulting from the final selection of the most effective strat-
egy (following exclusion of strategies being dominated or extend-
edly dominated [28]) can be displayed and also presented graphi-
cally on the cost-effectiveness plane (cost vs. QALY) by showing
which strategy was selected as most effective and marking the
strategies that have been excluded as being extendedly domi-
nated by another strategy. This approach has been adopted by
the authors in a NICE appraisal of the use of TNF-alpha inhibi-
tors in treatment of psoriatic arthritis [26].
There are some limitations to TIDI that can be explored
through further work. For example the influence analysis is lim-
ited when more than two strategies are being compared and in
such cases tornado plots cannot provide definitive answers as
they represent a single outcome (such as ICER or INMB) comparing
only two interventions. To compensate for this limitation tornado
plots for pair wise comparisons can be used to help to shed some
light on what is important in the decisionmodel. Further method-
ological considerations should aim to develop adequate tools
equivalent to tornado plots which would address these limita-
tions. Influence analysis not only assists in establishing which
parameters can have the strongest impact on the estimates of the
decision model, but potentially it can also be used to recommend
further research in order to reduce uncertainty of some key pa-
rameters. To this end, it would be possible to include value of
information calculations [29] within TIDI.
It may not be possible to use TIDI to run much more complex
models (than the one used as an example here) in real time as it
may take too much time to execute them. One solution to this
problem, which was adopted in the NICE appraisal of the use of
anti-TNFs in treatment of psoriatic arthritis [26], is to run only a
deterministic model in real time. Obtained results can later be
confirmed by the full stochastic model. Further work needs to be
carried out to develop optimization methods for complex models
so that it is possible to run them in real time during committee
meetings. There is a lot of scope for further development of TIDI,
for example it could include interactive tools for elicitation of ex-
pert opinions relating to bias in themeta-analysis module (as cur-
rently programmed for the anti-D example only existing elicita-
tions can be incorporated). The meta-analysis module could also
contain a tool for detecting and adjusting for publication bias and
displaying funnel plots [30], and also for incorporation of empirical
estimates of bias [31].
There are some technical challenges regarding the installation
of the interface. This is due to the need to install multiple pieces of
software in specific directories (as described in Appendix A). Our
primary aim has been to provide a “proof of concept” integrated
interactive approach to decision modeling, produce two working
examples, and use one of those examples in a “real life” situation.
As it stands, TIDI is not a consumer product (and we are not guar-
anteeing the application available is without bugs), but, since the
only piece of software used which is not freeware is the widely
used Excel, the approach should not be financially prohibitive.
Although furtherdevelopment toproduceasoftwareprogramfor the
front end to Excel allowing the creationofTIDI interfaceswithout the
need to program in VBA would be desirable, it would be a major
undertaking; if it were to have desirable levels of flexibility. There-
fore, a successful application of such an interface will require some
(additional) programming skills from those conducting HTA, but we
hope our illustrative example will demonstrate much of what is re-
quired.We also hope to secure funding to enable us to produce tuto-
rialmaterial in thenear future.Whilewe, the analysts, operatedTIDI
at the pilot NICE appraisal committee, we believe the interface was
straight forward enough that a committeemember could have done
the job with less than 1 hour of training.
There aremany advantages of a TIDI-type approach to decision
modeling over the non-integrated two-step approach and the in-
tegrated, but not interactive, one-step approach described in the in-
troduction. We believe that producing an interactive graphical rep-
resentationof results of theseusually complexanalysesusingauser-
friendly Excel interface provides added value to the decisionmodels
by facilitating in-depth access to the details of themodel structure to
the decisionmakers and other stakeholders, adding to the transpar-
ency of the decision-making process.
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